Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden

TY - JOUR

T1 - Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden

AU - Dissemond, Joachim

AU - Augustin, Matthias

AU - Dietlein, Michael

AU - Keuthage, Winfried

AU - Läuchli, Severin

AU - Lobmann, Ralf

AU - Münter, Karl-Christian

AU - Stücker, Markus

AU - Traber, Jürg

AU - Vanscheidt, Wolfgang

AU - Strohal, Robert

PY - 2020/10

Y1 - 2020/10

N2 - Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was a double-blind RCT with 187 patients with VLU. The SPID study was a pilot study with 33 patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88 patients with VLU in different phases of healing. In the REALITY study, a pooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, a significant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.

AB - Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was a double-blind RCT with 187 patients with VLU. The SPID study was a pilot study with 33 patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88 patients with VLU in different phases of healing. In the REALITY study, a pooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, a significant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.

KW - Anti-Ulcer Agents/pharmacology

KW - Humans

KW - Sucrose/analogs & derivatives

KW - Varicose Ulcer/drug therapy

KW - Wound Healing

U2 - 10.1007/s00105-020-04637-9

DO - 10.1007/s00105-020-04637-9

M3 - SCORING: Review

C2 - 32638031

VL - 71

SP - 791

EP - 801

JO - HAUTARZT

JF - HAUTARZT

SN - 0017-8470

IS - 10

ER -